Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients

Annals of Oncology

Volumn 21, Issue 11, 2010, Pages 2267-2271

  Schroeder, T ^a   Ruf, L ^a   Bernhardt, A ^a   Hildebrandt, B ^a   Aivado, M ^a,b   Aul, C ^c   Gattermann, N ^a   Haas, R ^a   Germing, U ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b GLAXOSMITHKLINE   (United States)

^c ST JOHANNES HOSPITAL   (Germany)

Author keywords

Clonality; HUMARA; ICUS; MDS; X chromosome inactivation

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW DISEASE; CLONAL VARIATION; CONTROLLED STUDY; CYTOPENIA; DISEASE CLASSIFICATION; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN ANDROGEN RECEPTOR GENE BASED ASSAY; IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; X CHROMOSOME INACTIVATION;

EID: 77958510028     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq233     Document Type: Article

References (25)

1. Germing U, Aul C, Niemeyer CM et al. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol 2008; 87(9): 691-699.
2. Brunning RD, Orazi A, Germing U et al. Myelodysplastic syndromes. In Swerdlow SH, Campo E, Harris NL et al. (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer [IARC] 2008; 88-107.
3. Valent P, Horny HP, Bennett JM et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007; 31(6): 727-736. Review.
4. Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest 2009; 39(7): 548-553.
5. Wimazal F, Fonatsch C, Thalhammer R et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res 2007; 31(11): 1461-1468.
6. Hanson CA, Hoyer JD, Zakko L et al. Is idiopathic cytopenia of undetermined significance (ICUS) a valid clinical concept? A longitudinal clinicopathological study. Leuk Res 2009; 33 (Suppl 1): S109-S111.
7. Allen RC, Zoghbi HY, Moseley AB et al. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet 1992; 51(6): 1229-1239.
8. Lyon MF. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 1961; 190: 372-373.
9. Chen GL, Prchal JT. X-linked clonality testing: interpretation and limitations. Blood 2007; 110(5): 1411-1419. Review.
10. Wang L, Zheng L, Wang SY et al. Clonal analysis of gastric carcinoma and precancerous lesions and its relation to Ki-67 protein expression. Neoplasma 2009; 56(1): 48-55.
11. Li H, Chen Q, Zhu R et al. Clonality analysis of intraductal proliferative lesions using the human androgen receptor assay. Neoplasma 2007; 54(6): 490-494.
12. Levine RL, Belisle C, Wadleigh M et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107(10): 4139-4141.
13. Gale RE, Linch DC. Clonality studies in acute myeloid leukemia. Leukemia 1998; 12(2): 117-120. Review.
14. Boudewijns M, van Dongen JJ, Langerak AW. The human androgen receptor X-chromosome inactivation assay for clonality diagnostics of natural killer cell proliferations. J Mol Diagn 2007; 9(3): 337-344.
15. Willman CL, Busque L, Griffith BB et al. Langerhans'-cell histiocytosis (histiocytosis X)-a clonal proliferative disease. N Engl J Med 1994; 331(3): 154-160.
16. Delforge M, Demuynck H, Verhoef G et al. Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. Br J Haematol 1998; 102(2): 486-494.
17. Aivado M, Rong A, Germing U et al. Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis. Br J Haematol 2000; 110(4): 884-886.
18. Aivado M, Rong A, Stadler M et al. Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 2002; 68(4): 210-216.
19. Sashida G, Tauchi T, Katagiri T et al. Transformation of severe aplastic anemia into myelodysplastic syndrome with monosomy 7: monoclonal origin detected by HUMARA gene analysis during the aplastic anemia phase. Haematologica 2000; 85(6): 665-666.
20. Mach-Pascual S, Legare RD, Lu D et al. Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: a single institution study. Blood 1998; 91(12): 4496-4503.
21. Haase D, Germing U, Schanz J et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110(13): 4385-4395.
22. Gale RE, Linch DC. Interpretation of X-chromosome inactivation patterns. Blood 1994; 84(7): 2376-2378.
23. Gale RE, Fielding AK, Harrison CN, Linch DC. Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Br J Haematol 1997; 98(3): 512-519.
24. Agarwal N, Nussenzveig RH, Swierczek SI et al. Does HUMARA assay for assessment of clonal hematopoiesis have shortcomings? Blood 2009; 114(11): 2357-2358. Author reply 2358-2359.
25. Busque L, Paquette Y, Provost S et al. Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies. Blood 2009; 113(15): 3472-3474.